meRfi®-GM
Allogeneic hematopoietic stem cell transplantation (allo HSCT)
Welcome to meRfi-GM!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Navigation
Contents
Allogeneic hematopoietic cell transplantation (allo-HCT) can be a curative therapy for patients with hematological malignancies. However, it poses a significant risk for post-transplant mortality due to graft-versus-host disease (GVHD). The number of allogeneic hematopoietic stem cell transplants performed worldwide is steadily increasing. Consequently, the absolute number of complications, particularly GVHD, also rises.
Allogeneic hematopoietic stem cell transplantation (HSCT) involves:
- Administration of a conditioning regimen that includes chemotherapy (CT) drugs, with or without radiation.
- Infusion of hematopoietic progenitor cells from healthy donors.
Hematopoietic stem cell transplantation allows for maximal chemoradiotherapy and subsequent bone marrow regeneration. However, it also involves spec…
References (Sources)
- Allogeneic Hematopoietic Cell Transplantation and Other Expensive Cellular Therapies: A Miracle for the Few but Off Limits to Many?
- Chimeric Antigen Receptor-modified Donor Lymphocyte Infusion Improves the Survival of Acute Lymphoblastic Leukemia Patients With Relapsed Diseases After Allogeneic Hematopoietic Stem Cell Transplantation
- Hematopoietic stem-cell transplantation
- Identification of NM23-H2 as a tumour-associated antigen in chronic myeloid leukaemia
- The Gut Microbiota and Hematopoietic Stem Cell Transplantation: Challenges and Potentials
- The Role of Fecal Microbiota Transplantation in the Treatment of Acute Graft-versus-Host Disease
- Use of CAR-T cells in allogeneic hematopoietic stem cell transplantation